ImmuPharma plc (LON:IMM – Get Free Report) was up 4.2% on Friday . The stock traded as high as GBX 4.50 ($0.06) and last traded at GBX 3.75 ($0.05). Approximately 14,017,531 shares traded hands during mid-day trading, a decline of 25% from the average daily volume of 18,651,375 shares. The stock had previously closed at GBX 3.60 ($0.04).
ImmuPharma Stock Performance
The business has a 50 day simple moving average of GBX 1.71 and a 200-day simple moving average of GBX 1.72. The firm has a market cap of £16.57 million, a price-to-earnings ratio of -398.00 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Articles
- Five stocks we like better than ImmuPharma
- What is Put Option Volume?
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- 3 Monster Growth Stocks to Buy Now
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- How to Invest in Blue Chip Stocks
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.